Recombinant Human ACVR2B protein(Met1-Thr134), His-tagged

• Cat.No.: ACVR2B-197H
• Product Overview: Recombinant Human ACVR2B (NP_001097.2) (Met 1-Thr 134) was expressed in HEK293, fused with a polyhistidine tag at the C-terminus.

Specification

• Species: Human
• Source: HEK293
• Tag: His
• Protein Length: 1-134 a.a.
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Bio-activity: 1. Measured by its ability to bind biotinylated Human INHBA-his in functional ELISA. 2. Measured by its ability to bind biotinylated Mouse INHBA-his in functional ELISA. 3. Measured by its ability to neutralize Activin-mediated inhibition on MPC11 cell proliferation. The ED50 for this effect is typically 0.3-2 μg/mL in the presence of 10 ng/mL recombinant Activin A.
• Molecular Mass: The recombinant human ACVR2B comprises 127 amino acids and predicts a molecular mass of 15 kDa. As a result of glycosylation, rh ACVR2B migrates as an approximately 33-38 kDa protein in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 97 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: ACVR2B activin A receptor, type IIB [ Homo sapiens ]
• Official Symbol: ACVR2B
• Synonyms: ACVR2B; activin A receptor, type IIB; activin receptor type-2B; ActR IIB; HTX4; ACTRIIB; ActR-IIB
• Gene ID: 93
• mRNA Refseq: NM_001106
• Protein Refseq: NP_001097
• MIM: 602730
• UniProt ID: Q13705

Case Study

Case 1: Swan J, et al. Biomed Pharmacother. 2024

Blocking ACVR2 signaling can boost insulin sensitivity, aid weight loss, and restore heart function in heart failure models, but it isn't clear how it might treat obesity-related heart and metabolic issues. In a study investigating ACVR2's role in metabolic dysfunction-related fatty liver disease (MASLD), mice were fed a high-fat, high-sugar diet, and given an inhibitor called L-NAME in their water to induce hypertension. The mice, treated with a soluble ACVR2B decoy receptor (sACVR2B-Fc) for the last eight weeks, showed less liver trouble, with MASLD reduction and less fibrotic activity. Moreover, it lowered overall cholesterol, slowed down the whitening of brown adipose tissue, and enhanced heart diastolic function. Lab tests revealed that ACVR2 ligands like activin A, activin B, and GDF11 can trigger fibrotic signaling pathways and foster the growth of human cardiac fibroblasts.

Fig1. sACVR2B-Fc improved diastolic function (E/A) close to normal levels during the WD L-NAME pathology.

Fig2. WD L-NAME increased HMGCR expression, but sACVR2B-Fc had no effect in the liver.

Case 2: Huang Y, et al. Cell Rep. 2022

Activin receptor IIB (ACVR2B) is being recognized as a key player in osteoarthritis (OA), but its specific ligands and components were previously unknown. Recent findings suggest that an increase in ACVR2B and its complex could worsen cartilage damage in OA. Activin A, a ligand for ACVR2B, influences the expression of catabolic factors contributing to OA. Experiments show that mice with elevated Activin A levels suffer more cartilage damage, while those with reduced Activin A levels are better protected. Analysis indicates that the Activin A-ACVR2B pathway plays a role in generating reactive oxygen species (ROS) via Nox4. Mice lacking Nox4 show inhibition of OA when Activin A levels are high. Furthermore, NOX4 binds to ACVR2B-ACVR1B, boosting cartilage damage through SMAD2/3 signaling. These insights reveal that components like Activin A, ACVR2B, ACVR1B, Nox4, and AP-1-induced HIF-2α could accelerate OA. Reducing ACVR2B activity or blocking its interaction with Activin A prevents OA progression by interrupting this signaling pathway.

Fig1. Chondrocytes were transfected with WT ACVR2B or muACVR2B.

Fig2. Interaction of endogenous ACVR2B and ACVR1B heterodimers with endogenous Nox4.

Application

Human ACVR2B, also known as activin A receptor type 2B, is an enzyme that sits in the cell membrane and has a role in the activin receptor complex. It helps relay signals inside cells, influencing many bodily processes like how neurons develop and survive, how hair follicles grow, the production of hormones by the pituitary gland, healing of wounds, creation of the extracellular matrix, immune system suppression, and cancer development. This receptor is also crucial in regulating cells responsible for creating myelin in the central nervous system. It works with various proteins and can be found in many tissues, indicating its broad importance in cellular functions.

The recombinant human ACVR2B protein finds widespread use in both scientific research and industrial production. In research, it helps investigate biological processes such as how muscles grow, obesity, and metabolic diseases, enhancing our understanding of these complex areas. In industrial settings, ACVR2B is frequently used in creating new treatments for conditions like muscular dystrophy and muscle weakness. Its involvement in regulating cell signaling pathways makes it a vital instrument for exploring potential new therapies and spurring innovation and technological advancement in related sectors.

Fig1. Model for role of activin receptor signaling in oligodendrocyte lineage cells. (Yinan Hu, 2022)